Abstract
A new library of Aryl Isoxazole Incorporated Pyrimidin-2-yl)oxazolo[4,5-b]pyridine compounds 11a-j and their structures were characterized by analytical data. Further, the preliminary anticancer activity of the newly prepared compounds 11a-j was examined against four types of human cancer cell lines, breast cancer (MCF-7), lung cancer (A549), colon cancer (Colo-205) and ovarian cancer (A2780) by utilizing the MTT method. Most of the compounds displayed good to moderate activities as compared with the etoposide used as a positive control. Amon, five compounds 11a, 11b, 11h, 11i and 11j exhibited more potent activity than the positive control. Mainly, compound 11h displayed superior anticancer activity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
